Schering AG (NYSE: SHR; FSE: SCH) received approval in Finland, the first European country, for Nebido™, a new type of depot preparation for the treatment of hypogonadism (testosterone deficiency) in men. Following the European Mutual Recognition Process, Schering expects approval for Nebido™ to follow in more European countries in the course of 2004. In addition, Schering plans to apply for approval in Latin American countries and Canada next year.
"Requiring only four injections per year, Nebido™ represents a major improvement for men suffering from testosterone deficiency. Previously, patients received on average 22 injections per year. Additionally the unique formulation of Nebido™ allows for a blood level of testosterone within the physiological range and is therefore more compatible with the patients needs,"
Still, its not as advanced as it sounds. This is basically like Test w/ a Deca ester so for our purposes the injections would still need to be much more often. However, this is a cool choice for a cycle - could help cut down on injection frequency for Test quite a bit.
That is unless im missing something....
"Requiring only four injections per year, Nebido™ represents a major improvement for men suffering from testosterone deficiency. Previously, patients received on average 22 injections per year. Additionally the unique formulation of Nebido™ allows for a blood level of testosterone within the physiological range and is therefore more compatible with the patients needs,"
Still, its not as advanced as it sounds. This is basically like Test w/ a Deca ester so for our purposes the injections would still need to be much more often. However, this is a cool choice for a cycle - could help cut down on injection frequency for Test quite a bit.
That is unless im missing something....
Comment